U.S. Markets closed

Biogen price target raised to $355 from $291 at Canaccord

Canaccord believes Biogen's SMNRx/SMA opportunity is $2B+ in potential peak sales with potential 2017 approval. The firm believes the data is compelling and that Biogen will opt into the ISIS SMA program and has a high probability of success. Shares are Buy rated.